Sensory : pins and needles or numbness in feet and/or hands, or sometimes increased sensitivity to pain
Standard titration protocol from clinical trials The Phase 2 NEJM trial used the following escalation schedule for the 12 mg dose group: Weeks 1 through 4: 2 mg once weekly (subcutaneous) Weeks 5 through 8: 4 mg once weekly Weeks 9 through 12: 8 mg once weekly Week 13 and beyond: 12 mg once weekly (maintenance dose) For the 8 mg target dose, the schedule was: Weeks 1 through 4: 2 mg once weekly Weeks 5 through 8: 4 mg once weekly Week 9 and beyond: 8 mg once weekly (maintenance dose) These titration schedules are not suggestions
Comparison of vitamin E and propionyl-l-carnitine, separately or in combination, in patients with early chronic Peyronies disease: A double-blind, placebo controlled, randomized study
It is also one of the three actives in the Peptual transdermal patch he endorses, alongside BPC-157 and NAD+: BPC-157: ~2000 mcg NAD+: ~250 mg GHK-Cu: ~10 mg The patch combines tissue repair (BPC-157), cellular energy (NAD+), and collagen synthesis (GHK-Cu) in a sustained-release format (source)
While also meeting criteria for later fibromyalgia may be rare among patients treated promptly for early Lyme disease as a whole (1%) (87), earlier studies suggested that this overlap may be more common among the subset of patients with prolonged, persistent symptoms (8991)
Handling, preparation, and disposal should follow your institution's standard operating procedures
